SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3169)4/9/2018 8:31:22 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3202
 
Seems that AAV5 ( AMT-061) has lower pre-existing mAbs titar! They are going strait with dose of 2 x 10^13 gc/kg: clinicaltrials.gov



To: scaram(o)uche who wrote (3169)4/24/2018 4:45:02 PM
From: scaram(o)uche  Respond to of 3202
 
OT, again

>> Look at the daily chart for qure and once versus that for sgmo <<

And sgmo goes for $200m offering of common. Guess that could explain why it's come back so hard, BAML, J.P. Morgan and Cowen lubed. Strange time to get greedy. In the last month..... qure up 20%, once up 12%, sgmo down 21%.

There HAS to be perspective out there that I don't have. Anybody????? TIA.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News